Abstract 2134P
Background
Hodgkin’s lymphoma survivors (HLSs) are at risk for late effects due to their early age at diagnosis, multimodal therapy and long life expectancy. Among HLSs, we explored self-reported late effects, and assessed their information needs regarding lifestyle (diet and physical activity) and rehabilitation, in addition to need for long-term follow-up and factors associated with these needs.
Methods
HLSs treated 1997-2006 and aged 18-49 years at diagnosis were identified by the Norwegian Cancer Registry and invited to participate in this population-based, cross-sectional study consisting of a questionnaire, blood tests, clinical examination and echocardiography. Information regarding histology, stage and treatment was retrieved from medical records. Descriptive statistics and logistic regression models were used.
Results
Among the participants (n=304, 59% response rate), median age at diagnosis was 29 years (range 8-49), median age at survey 45 years (21-70), median observation time 16 years (10-22) and 48 % were females. Ninety percent had classical HL, 62% had stage I-IIA disease, 94% received chemotherapy and 77% radiotherapy. Seventy-four percent reported to have experienced ≥1 late effects; concentration/memory problems (29%), numbness/nerve pain (32%) and dental problems (27%) were the most common. Forty-one percent reported chronic fatigue (CF). One third reported to have received follow-up for late effects. A total of 64% wanted information about lifestyle and/or rehabilitation, and 58% wanted regularly follow-up for late effects. In the multivariable models, CF (OR 2.2, 95%CI 1.2-4.1), short education (2.2, 1.2-4.0), being physical inactive (2.0, 1.1-3.5) were associated with increased likelihood of need for information about lifestyle and/or rehabilitation. CF was associated with increased likelihood of need for follow-up for late effects (2.1, 1.3-3.6).
Conclusions
HLSs report a high level of late effects and only a small proportion receive follow-up for these problems. Chronic fatigue is associated with need for information and follow-up, indicating that these patients could benefit from a more structured model for long-term follow-up than what is currently available.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
Norwegian Cancer Society and the DAM foundation, project number 2019/FO247426; Norwegian Extra Foundation for Health and Rehabilitation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma
Presenter: Chi Cho
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07